Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

1 ArticlesPharma Sector

1 / 1

Cracking the Patent Code: Natco’s Winning Formula

Natco Pharma, a leader in APIs and niche generics, faces growth challenges post-Revlimid exclusivity in FY26, with semaglutide offering long-term ...

Jan 22, 2025

Natco-Pharma.jpg

Join Capitalmind Premium

Starts at ₹1,999/mo

Get access to our equity, fixed income, macro and personal finance research, model equity and fixed-income portfolios, exclusive apps, tutorials, and member community.